Atorvastatin did not prevent cardiovascular events or death in patients with type 2 diabetes receiving hemodialysis: COMMENTARY

Moist, Louise
January 2006
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p7
Academic Journal
This article comments on a study conducted to examine the efficacy of atorvastatin in preventing cardiovascular events or death in patients with type 2 diabetes receiving hemodialysis. Because cardiovascular disease is the leading cause of death among patients on dialysis, cholesterol-lowering therapy might be expected to have considerable benefit. Total cholesterol levels are positively correlated with mortality in the general population, but not in patients on dialysis, possibly because of concurrent malnutrition and inflammation. Cardiovascular disease in patients on dialysis has been increasingly attributed to nontraditional risk factors, including vascular calcification, hyperhomocysteinemia, elevated lipoprotein, anemia, malnutrition, and oxidative stress.


Related Articles

  • CoQ10 Improves Endothelial Function in Statin-Treated Diabetics. Kiefer, Dale // Life Extension;Jul2009, Vol. 15 Issue 7, p22 

    The article discusses a study on the benefits of coenzyme Q10 (CoQ10) in type 2 diabetes. According to a study by Australian researchers, C0Q10 is an important mitochondrial co-factor and a natural antioxidant. They found that it improves endothelial functions in diabetes patients who are...

  • Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Tousoulis, Dimitris; Antoniades, Charalambos; Vasiliadou, Carmen; Kourtellaris, Pantelis; Koniari, Katerina; Marinou, Kyriakoula; Charakida, Marietta; Ntarladimas, Loannis; Siasos, Gerasimos; Stefanadis, Christodoulos // Heart;Feb2007, Vol. 93 Issue 2, p244 

    The article discusses a study that determines the effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmetrical dimethyl arginine (ADMA) levels and the inflammatory process in patients with type 2 diabetes mellitus (DM). The study involved 41 patients with type 2 DM and no...

  • Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment. Farah, Raymond; Shurtz-Swirski, Revital; Lapin, Olga // Cardiovascular Diabetology;2008, Vol. 7, p1 

    Introduction: The metabolic deregulation associated with diabetes mellitus (DM) causes secondary pathophysiologic changes in multiple organ systems. Endothelial injury is induced by oxidative stress (OS) and inflammation. We have previously shown that DM type 2 patients are exposed to increased...

  • Statins and Diabetes: The Plot Thickens. Gastaldi, Giacomo; Philippe, Jacques // JGIM: Journal of General Internal Medicine;Nov2015, Vol. 30 Issue 11, p1572 

    The article looks into the association between the use of statin therapy and the development of type 2 diabetes. The results of several studies, including a retrospective cohort study by researcher I. Mansi and colleagues, which examined such association are discussed. The author suggests that...

  • The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes. Davenport, Colin; Ashley, David T.; O’Sullivan, Eoin P.; McHenry, Claire M.; Agha, Amar; Thompson, Christopher J.; O’Gorman, Donal J.; Smith, Diarmuid // Journal of Diabetes Research;4/30/2015, Vol. 2015, p1 

    Statin therapy improves lipid profiles and reduces vascular inflammation, but its effects on central arterial stiffness in type 2 diabetes are unclear. The aim of this study was to determine whether statin therapy reduces central arterial stiffness, in a dose-dependent manner, in male patients...

  • Effect of Pitavastatin on Type 2 Diabetic Nephropathy in KK-A[sup y]/Ta Mouse. Matsumoto, Masakazu; Tanimoto, Mitsuo; Gohda, Tomohito; Murakoshi, Maki; Tomino, Yasuhiko // Diabetes;Jun2007 Supplement 1, Vol. 56, pA600 

    Background. It is generally considered that 3-hydroxy-3 methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have renoprotective effects via a pathway independent of their cholesterol lowering cascade. In the kidneys of diabetic nephropathy patients, monomeric endothelial nitric...

  • Statin benefits outweigh risk of developing diabetes.  // Pulse;2/24/2010, Vol. 70 Issue 6, p11 

    The article explores the benefits of statins that outweigh the risk of developing type 2 diabetes.

  • 398 Effect of statins on the course of CHF in patients with type 2 diabetes mellitus.  // European Journal of Heart Failure. Supplements;Jun2005, Vol. 4 Issue 1, p88 

    An abstract of the article "Effect of Statins on the Course of CHF in Patients With Type 2 Diabetes Mellitus," by G. Arutyunov and A. Beituganov is presented.

  • Clinical briefs.  // New Zealand Doctor;3/10/2010, p24 

    This section offers clinical news briefs including the role of statins in raising the relative risk of developing type 2 diabetes by nine percent, the risk posed by paroxetine to women taking tamoxifen for breast cancer, and the role of aspirin in helping women with breast cancer survive.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics